#ASCO25 Ed Book: From Africa, India 🇮🇳 & LATAM Brasil 🇧🇷 and México 🇲🇽, proposals to improve global cancer care for all patients. ascopubs.org/doi/pdfdirect/… Regina Barragan-Carrillo Rodrigo Dienstmann_MD_MBA Frederick Chite MD FASCO Dr Dinesh Pendharkar MD PhD FASCO Instituto Nacional de Cancerología ASCO

Just out in press in Radiotherapy & Oncology systematic review of TCI in ES-SCLC. 📢cTRT: 👉cTRT combined with ChemoIO ⬆️ OS + PFS 👉⬆️OS + PFS in pts with brain mets 👉cTRT with ChemoIO⬆️brain mets-free survival 👉⬆️ incidence of pneumonitis + esophagitis 🔗sciencedirect.com/science/articl…

Treatment Selection for EGFR-Mutated Advanced NSCLC: Efficacy, Toxicity, and Quality of Life Charu Aggarwal, MD, MPH, FASCO gilberto lopes Oncology News Central oncologynewscentral.com/treatment-sele…

IV fluids guide

كيف تختار التحليل الاحصائي المناسب لبحثك او تقريرك 👇🏼

Next-generation proteomics improves lung cancer risk prediction ➡️ buff.ly/HuGy5mW #Proteomics This is a novel blood-based protein marker model designed to improve the identification of 👫at high risk for🫁cancer. Using advanced next-generation proteomics, 4

Monitoring of circulating tumour DNA allows early detection of disease relapse in patients with operable breast cancer 👉 buff.ly/eiXX4Km #ctDNA #BCSM #LiquidBiopsy

The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon shorturl.at/8lBd4

Happy New Year from UCAN Ireland team 🎊 Thank you for the incredible support since we launched. We couldn't do it without you! May your New Year be filled with hope and positivity ❤️⭐

Every January, oncologists promise the same thing. “I’ll read trials more carefully this year.” Then we read the abstract conclusion and move on. Here’s the uncomfortable truth: 📣 Abstracts sell drugs. 📊 Data tells the truth. Let me show you how to autopsy a Phase III

Bladder preservation is a deliberate, evidence-based choice — not a compromise ❗️ 📌 Key takeaways from #IBCG consensus recommendations on bladder preservation therapy (BPT) in #MIBC: patient selection, trimodal therapy, and surveillance. #UroOncology #BladderCancer #MIBC #TMT

ICI resistance in dMMR/MSI-H CRC 🚀 ICIs = SoC, but ~1/3 develop resistance 🧩 Intrinsic + extrinsic mechanisms (beyond misdiagnosis) 🎯 Need better biomarkers beyond dMMR/MSI-H 🔬 New approaches: combos, novel targets, microbiome modulation ➡️ Roadmap to optimize ICI

Management of Cancer During Pregnancy: ASCO Guideline Journal of Clinical Oncology doi.org/10.1200/JCO-25… 👏Very useful guidance on the recommended management of cancer in pregnant patients 👉Systematic review of 450 studies 👉Many systemic therapies are contraindicated ESMO - Eur. Oncology ASCO

7 questions to ask when evaluating a noninferiority trial: While most physicians are accustomed to evaluating randomized placebo-controlled studies, many are less familiar with the purpose and takeaway of noninferiority trials acrobat.adobe.com/id/urn:aaid:sc…

😐

BREAKING 1,280 Saudi nationals are currently training as doctors in Canadian hospitals. These visa trainees are funded by the Kingdom of Saudi Arabia. They will not work in Canadian hospitals after their training. At the same time, thousands of Canadians who graduate from

🌟 #TASLC26 #NTUCC 🔥High Hits for Stage IV #EGFR mutated NSCLC Tx 2025 ☑️Multiple options @ 1st line: FLAURA2, MARIPOSA, Nothstar ☑️New options against resistance: Dato-DXd, Sac-TMT, MET TKIs, MARIPOSA-2 🎙️ Daniel Tan 台灣肺癌研究學會 IASLC OncoAlert #LCSM LARVOL

How long should immunotherapy continue in NSCLC: 2 years or indefinitely? Curioni_Oncology_MD highlighted real-world data with >14,000 patients showing no major OS difference between fixed and extended ICI duration. For now, treatment decisions remain individualized, guided by protocol,